Related Experiment Video
Updated: Jan 12, 2026

Author Spotlight: Advancing Organoid Generation for Drug Development Using iPSCs
Published on: March 15, 2024
Persona-driven generative AI in pharmaceuticals
Yun Wan1, Makoto Nakayama2, Cesar Floyd Aldana3
1University of Houston-Downtown, 1 Main Street, Houston, TX 77002, United States.
None:
Persona-driven generative artificial intelligence (GenAI) represents a transformative approach to pharmaceutical innovation, providing structured frameworks that enhance AI-human collaboration across drug development. We examine recent applications (2023-2025) spanning target identification, clinical development, regulatory intelligence, and patient communication. Key developments include AlphaFold 3's protein structure prediction breakthroughs, regulatory validation of digital twin methodologies, and AI-powered regulatory intelligence systems. Using contextual priming and specialized domain expertise, personas significantly improve GenAI performance in pharmaceutical contexts. Although these tools have demonstrated 60-70% timeline reductions and enhanced clinical trial efficiency, challenges remain in hallucination mitigation, bias management, and regulatory validation. This assessment highlights transformative opportunities while addressing critical implementation barriers for widespread pharmaceutical adoption.
More Related Videos
Related Concept Videos
Non-equilibrium in the Cell
Microorganisms in Medicine and Therapeutics
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Drug Discovery: Overview
Pharmaceutical Equivalents
Prodrugs
Prodrugs help overcome...

